



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose, and have indicated that their presentation or discussion will not include off-label or unapproved product usage.

Nadeem Abu-Rustum, M.D.
Starr Mautner, M.D.

Ashwin Mehta, M.D.
Miguel Medina, M.D.

Eric Schroeder, M.D.

Robert Coleman, M.D., FACOG, FACS, faculty for this educational activity, is a researcher for AstraZeneca, Clovis Oncology, Genelix Corporation, Genmab Biotechnology, Merck, ImmunoGen and Genentech Biotechnology; a consultant for Agenus Biotechnology and Alkermes; and an adviser for VBL Therapeutics, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

John Diaz, M.D., co-director of this educational activity, is a researcher for Merck & Co. and AstraZeneca, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Reshma Mahtani, D.O., co-director of this educational activity, is a consultant/adviser for Agendia, Amgen, AstraZeneca, Daiichi-Sankyo, Eisai Pharmaceutical, Gilead Science, Hologic, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, Seagen and Puma Biotechnology, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Martin Martino, M.D., faculty for this educational activity, is on the advisory boards for AstraZeneca, Merck, Pfizer, Artios Pharma Limited, Daiichi Sankyo Pharmaceutical, Epic Sciences, Tempus and Zenith Pharma, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Kathleen Moore, M.D., M.S., faculty for this educational activity, is a researcher for PTC Therapeutics Pharmaceutical, Eli Lilly, Merck, Verastem Oncology, GSK plc Pharmaceutical, Genentech Biotechnology, Clovis Oncology, AstraZeneca, Aravive, Alkermes, Aadi Bioscience, Blueprint Medicines, Eisai Pharmaceutical, EMD Serono, Jiangsu Hengrui Medicine, ImmunoGen and GOG Partners, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Rita Nanda, M.D., faculty for this educational activity, is a researcher for Arvinas Pharmaceutical, Celgene Pharmaceutical, Corcept Therapeutics Pharmaceutical, AstraZeneca, Gilead Sciences, Merck & Co. Pharmaceutical, Seagen Biotechnology, Genentech Biotechnology, ImmunoGen, Roche Holding AG Pharmaceutical, OBI Pharma, OncoSec Medical, Pfizer, Relay Therapeutics, Sun Pharmaceutical Industries, Taiho Pharmaceutical, BeyondSpring Biotech, Fujifilm Pharmaceuticals U.S.A., GE HealthCare, Sanofi Pharmaceutical, Infinity Pharmaceuticals and iTeos Therapeutics, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Anne O'Dea, M.D., faculty for this educational activity, is a speaker and consultant for Puma Biotechnology, Pfizer Pharmaceutical, AstraZeneca, Daiichi-Sankyo, Gilead Sciences, Seagen Biotechnology and Novartis Pharmaceuticals, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Matthew A. Powell, M.D., faculty for this educational activity, is a consultant for Merck, AstraZeneca, Eisai Pharmaceutical, GSK plc Pharmaceutical, Clovis Oncology and Seagen Biotechnology, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Mark Robson, M.D., faculty for this educational activity, is a researcher for AstraZeneca, Merck and Pfizer, and an adviser for Artios Pharma Limited, Daiichi-Sankyo, Epic Sciences, Tempus and Zenith Pharma, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content do not have relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*